[en] Centronuclear myopathies (CNM) are a group of rare inherited muscular disorders leading to a significantly reduced quality of life and lifespan. To date, CNM epidemiologic reports provide limited incidence and prevalence data. Here, an integrated model utilizing available literature is proposed to obtain a better estimate of overall CNM patient numbers by age, causative gene, severity and geographic region. This model combines published epidemiology data and extrapolates limited data over CNM subtypes, resulting in patient numbers related to age and disease subtype. Further, the model calculates a CNM incidence twofold the current estimates. The estimated incidence of 17 per million births for severe X-linked myotubular myopathy (XLMTM), the main subtype of CNM, corresponds to an estimated prevalence of 2715 in the US, 1204 in the EU, 688 in Japan and 72 in Australia. In conclusion, the model provides an estimate of the CNM incidence, prevalence and survival, and indicates that the current estimates do not fully capture the true incidence and prevalence. With rapid advances in genetic therapies, robust epidemiologic data are needed to further quantify the reliability of incidence, prevalence and survival rates for the different CNM subtypes.
Disciplines :
Pediatrics Neurology
Author, co-author :
Vandersmissen, I.
Biancalana, V.
Servais, Laurent ; Université de Liège - ULiège > Département des sciences cliniques > Neuropédiatrie
Dowling, J. J.
Vander Stichele, G.
Van Rooijen, S.
Thielemans, L.
Language :
English
Title :
An integrated modelling methodology for estimating the prevalence of centronuclear myopathy.
Publication date :
2018
Journal title :
Neuromuscular Disorders
ISSN :
0960-8966
eISSN :
1873-2364
Publisher :
Elsevier, Netherlands
Volume :
28
Issue :
9
Pages :
766-777
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2018 Elsevier B.V. All rights reserved.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Smith, BK, Goddard, M, Childers, MK, Respiratory assessment in centronuclear myopathies. Muscle Nerve 50 (2014), 315–326, 10.1002/mus.24249.
Laporte, J, Hu, LJ, Kretz, C, Mandel, JL, Kioschis, P, Coy, JF, et al. A gene mutated in x-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet 13 (1996), 175–182, 10.1038/ng0696-175.
Bitoun, M, Maugenre, S, Jeannet, P-Y, Lacène, E, Ferrer, X, Laforêt, P, et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet 37 (2005), 1207–1209, 10.1038/ng1657.
Böhm, J, Biancalana, V, Malfatti, E, Dondaine, N, Koch, C, Vasli, N, et al. Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations. Brain 137 (2014), 3160–3170, 10.1093/brain/awu272.
Nicot, AS, Toussaint, A, Tosch, V, Kretz, C, Wallgren-Pettersson, C, Iwarsson, E, et al. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet 39 (2007), 1134–1139, 10.1038/ng2086.
Wilmshurst, JM, Lillis, S, Zhou, H, Pillay, K, Henderson, H, Kress, W, et al. RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann Neurol 68 (2010), 717–726, 10.1002/ana.22119.
Agrawal, PB, Pierson, CR, Joshi, M, Liu, X, Ravenscroft, G, Moghadaszadeh, B, et al. SPEG interacts with myotubularin, and its deficiency causes centronuclear myopathy with dilated cardiomyopathy. Am J Hum Genet 95 (2014), 218–226, 10.1016/j.ajhg.2014.07.004.
Ceyhan-Birsoy, O, Agrawal, PB, Hidalgo, C, Schmitz-Abe, K, DeChene, ET, Swanson, LC, et al. Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy. Neurology 81 (2013), 1205–1214, 10.1212/WNL.0b013e3182a6ca62.
Herman, GE, Finegold, M, Zhao, W, De Gouyon B, MetzenbergA, Medical complications in long-term survivors with x-linked myotubular myopathy. J Pediatr 134 (1999), 206–214, 10.1016/S0022-3476(99)70417-8.
Bertini, E, Biancalana, V, Bolino, A, Buj Bello, A, Clague, M, Guicheney, P, et al. 118th ENMC international workshop on advances in myotubular myopathy. 26-28 September 2003, Naarden, The Netherlands. (5th workshop of the international consortium on myotubular myopathy) Neuromuscul Disord 14 (2004), 387–396, 10.1016/j.nmd.2004.04.002.
Laporte, J, Blondeau, F, Buj-Bello, A, Mandel, JL, The myotubularin family: from genetic disease to phosphoinositide metabolism. Trends Genet 17 (2001), 221–228, 10.1016/S0168-9525(01)02245-4.
Jungbluth, H, Wallgren-Pettersson, C, Laporte, JF, 198th ENMC international workshop: 7th workshop on centronuclear (myotubular) myopathies. 31st May - 2nd June 2013, Naarden, The Netherlands Neuromuscul Disord 23 (2013), 1033–1043, 10.1016/j.nmd.2013.08.006.
Amburgey, K, McNamara, N, Bennett, LR, McCormick, ME, Acsadi, G, Dowling, JJ, Prevalence of congenital myopathies in a representative pediatric united states population. Ann Neurol 70 (2011), 662–665, 10.1002/ana.22510.
Verhaart, IEC, Robertson, A, Leary, R, McMacken, G, König, K, Kirschner, J, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol 264 (2017), 1465–1473, 10.1007/s00415-017-8549-1.
Verhaart, IEC, Robertson, A, Wilson, IJ, Aartsma-Rus, A, Cameron, S, Jones, CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis, 12, 2017, 124, 10.1186/s13023-017-0671-8.
Institute of mediciene. Rare diseases and orphan products: accelerating research and development. 2010, National Academies Press, Washington, D.C., 10.17226/12953.
McEntagart, M, Parsons, G, Buj-Bello, A, Biancalana, V, Fenton, I, Little, M, et al. Genotype-phenotype correlations in x-linked myotubular myopathy. Neuromuscul Disord 12 (2002), 939–946, 10.1016/S0960-8966(02)00153-0.
Biancalana V. UMD-MTM1 registry n.d.
Biancalana, V, Scheidecker, S, Miguet, M, Laquerrière, A, Romero, NB, Stojkovic, T, et al. Affected female carriers of MTM1 mutations display a wide spectrum of clinical and pathological involvement: delineating diagnostic clues. Acta Neuropathol, 2017, 10.1007/s00401-017-1748-0.
Biancalana, V, Beggs, A, Das, S, Jungbluth, H, Kress, W, Nishino, I, et al. Clinical utility gene card for: centronuclear and myotubular myopathies. Eur J Hum Genet, 2012, 20.
Fattori, F, Maggi, L, Bruno, C, Cassandrini, D, Codemo, V, Catteruccia, M, et al. Centronuclear myopathies: genotype–phenotype correlation and frequency of defined genetic forms in an Italian cohort. J Neurol 262 (2015), 1728–1740, 10.1007/s00415-015-7757-9.
Lally, C, Jones, C, Farwell, W, Reyna, SP, Cook, SF, Flanders, WD, Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. Orphanet J Rare Dis, 12, 2017, 175, 10.1186/s13023-017-0724-z.
Lukacs, Z, Nieves Cobos, P, Wenninger, S, Willis, TA, Guglieri, M, Roberts, M, et al. Prevalence of pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. Neurology 87 (2016), 295–298, 10.1212/WNL.0000000000002758.
Bohm, J, Biancalana, V, DeChene, ET, Bitoun, M, Pierson, CR, Schaefer, E, et al. Mutation spectrum in the large gtpase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Hum Mutat 33 (2012), 949–959, 10.1002/humu.22067.
Bitoun, M, Bevilacqua, JA, Prudhon, B, Maugenre, S, Taratuto, AL, Monges, S, et al. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. Ann Neurol 62 (2007), 666–670, 10.1002/ana.21235.
Werlauff, U., Petri, H., Witting, N., Vissing, J, Frequency and phenotype of myotubular myopathy amongst danish patients with congenital myopathy older than 5 years. J Neuromuscul Dis 2 (2015), 167–174.
Savarese, M, Musumeci, O, Giugliano, T, Rubegni, A, Fiorillo, C, Fattori, F, et al. Novel findings associated with MTM1 suggest a higher number of female symptomatic carriers. Neuromuscul Disord 26 (2016), 292–299, 10.1016/j.nmd.2016.02.004.
Nigro, Vincenzo, Savarese, M, Next-generation sequencing approaches for the diagnosis of skeletal muscle disorders. Curr Opin Neurol 29 (2016), 621–627.
Farrar, MA, Vucic, S, Johnston, HM, du Sart, D, Kiernan, MC, Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr 162 (2013), 155–159, 10.1016/j.jpeds.2012.05.067.
Tassie, B, Isaacs, D, Kilham, H, Kerridge, I, Management of children with spinal muscular atrophy type 1 in Australia. J Paediatr Child Health 49 (2013), 815–819, 10.1111/jpc.12291.
Amburgey, K, Tsuchiya, E, de Chastonay, S, Glueck, M, Alverez, R, Nguyen, C-T, et al. A natural history study of X-linked myotubular myopathy. Neurology, 2017, 10.1212/WNL.0000000000004415 10.1212/WNL.0000000000004415.
Annoussamy, M, Lilien, C, Gidaro, T, Gargaun, E, Che, V, Schara, U, et al. Baseline data from patients with myotubular myopathy enrolled in a European prospective and longitudinal natural history study. Neuromuscul Disord 26 (2016), S116–S117, 10.1016/j.nmd.2016.06.114.
Roy, AJ, Van den Bergh, P, Van Damme, P, Doggen, K, Van Casteren, V, Early stages of building a rare disease registry, methods and 2010 data from the belgian neuromuscular disease registry (BNMDR). Acta Neurol Belg 115 (2015), 97–104, 10.1007/s13760-014-0320-0.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
